Collaborative community based care for people and their families living with schizophrenia in India: protocol for a randomised controlled trial by Chatterjee, Sudipto et al.
STUDY PROTOCOL Open Access
Collaborative community based care for people
and their families living with schizophrenia in
India: protocol for a randomised controlled trial
Sudipto Chatterjee
1,7,8*, Morven Leese
2, Mirja Koschorke
3, Paul McCrone
2, Smita Naik
1, Sujit John
4,
Hamid Dabholkar
5, Kimberley Goldsmith
2, Madhumitha Balaji
1, Mathew Varghese
6, Rangaswamy Thara
4,
Vikram Patel
1,3, Graham Thornicroft
2, The COmmunity care for People with Schizophrenia in India (COPSI) group
Abstract
Background: There is a large treatment gap with few community services for people with schizophrenia in low
income countries largely due to the shortage of specialist mental healthcare human resources. Community based
rehabilitation (CBR), involving lay health workers, has been shown to be feasible, acceptable and more effective
than routine care for people with schizophrenia in observational studies. The aim of this study is to evaluate
whether a lay health worker led, Collaborative Community Based Care (CCBC) intervention, combined with usual
Facility Based Care (FBC), is superior to FBC alone in improving outcomes for people with schizophrenia and their
caregivers in India.
Methods/Design: This trial is a multi-site, parallel group randomised controlled trial design in India.
The trial will be conducted concurrently at three sites in India where persons with schizophrenia will be screened
for eligibility and recruited after providing informed consent. Trial participants will be randomly allocated in a 2:1
ratio to the CCBC+FBC and FBC arms respectively using an allocation sequence pre-prepared through the use of
permuted blocks, stratified within site. The structured CCBC intervention will be delivered by trained lay community
health workers (CHWs) working together with the treating Psychiatrist. We aim to recruit 282 persons with
schizophrenia. The primary outcomes are reduction in severity of symptoms of schizophrenia and disability at 12
months. The study will be conducted according to good ethical practice, data analysis and reporting guidelines.
Discussion: If the additional CCBC intervention delivered by front line CHWs is demonstrated to be effective and
cost-effective in comparison to usually available care, this intervention can be scaled up to expand coverage and
improve outcomes for persons with schizophrenia and their caregivers in low income countries.
Trial registration: The trial is registered with the International Society for the Registration of Clinical Trials and the
allocated unique ID number is ISRCTN 56877013.
Background
Schizophrenia is a severe mental disorder that usually has
an onset in early adulthood and is often associated with
persistent or relapsing symptoms and a range of other
adverse outcomes [1,2]. Even though a low prevalence
disorder, schizophrenia contributes an estimated 1.1% of
the total Disability Adjusted Life Years (DALY’s) and
9.5% of the total DALY’s attributable to the
neuropsychiatric disorders [3] in South East Asia making
it a priority public health concern for the region. There is
international consensus that care for people with schizo-
phrenia should largely be delivered in community set-
tings for the best outcomes [4]. While in high resource
countries, community care is the norm, in low income
countries, the availability of community services is the
exception [5]. Thus, for the majority of persons with
schizophrenia and their caregivers in low income coun-
tries, including in India, there is little access to any care
[6]. Addressing this ‘treatment gap’ by scaling up
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vices for persons with schizophrenia is an urgent public
health and ethical priority in countries like India [7].
Scaling up of community services in low income coun-
tries faces challenges like the paucity of specialist
resources and the lack of evidence around the effective-
ness, costs and processes involved in delivering commu-
nity based interventions. One method that specifically
addresses the challenges of the lack of specialist
resources, accessibility and inequity in care provision is
the Community Based Rehabilitation (CBR) strategy for
persons with disabilities- a health and social intervention
that is largely implemented by appropriately trained, lay
persons within community settings [8]. In addition, the
CBR method has a strong focus on empowerment of ser-
vice users, social inclusion, livelihood support and equal-
ising of opportunities for people with disabilities; all of
these are of particular relevance to persons with schizo-
phrenia. A non-randomised controlled study from rural
India showed that CBR using trained lay community
workers was feasible and improved outcomes for people
with schizophrenia, compared with routine outpatient
care [9]. A more recent study from the same site has
described the impact of specific components of the com-
plex intervention on long-term outcomes in people with
schizophrenia [10]. These encouraging results need to be
rigorously tested through a randomized controlled trial.
If demonstrated to be clinically effective and affordable in
comparison to usually available care (i.e. facility based
care) alone, such interventions can be scaled up expand
coverage and improve outcomes of persons with schizo-
phrenia and their caregivers in low income countries by
using available and low cost human resources.
Objectives
The objectives of the trial are: firstly, to test the hypotheses
that usual, Facility-Based Care (FBC), when combined with
a Collaborative Community-Based Care intervention
(CCBC), will be superior to Facility-Based Care alone in
improving a range of outcomes in people with schizophre-
nia and their caregivers and, secondly, to determine if the
CCBC intervention is cost effective in India.
The primary objectives of the trial are to determine
whether the FBC+CCBC intervention will be superior to
FBC alone in:
i) reducing symptoms of schizophrenia at 12 months, and
ii) reducing disability related to schizophrenia over 12
months.
In persons with schizophrenia, the secondary objectives
are to determine whether, FBC+CCBC will be more
effective than FBC alone, in:
￿ improving adherence to antipsychotic treatment
￿ reducing experiences of stigma and discrimination
For caregivers of people with schizophrenia,t h e
secondary objectives are to determine
whether, FBC+ CCBC will be superior to FBC alone, in:
￿ improving their knowledge and attitudes about the
illness
￿ reducing their burden of caring
￿ reducing experiences of stigma and discrimination.
The health economic objective is to compare the costs
and assess the cost-effectiveness and cost-utility of the
FBC+ CCBC intervention compared to FBC alone.
The COPSI trial is a collaborative effort between multi-
ple institutions and individual Psychiatrists at the Indian
sites. The lead institution is the Institute of Psychiatry
(IoP), Kings’ College, London, while the partner organiza-
tions are the London School of Hygiene and Tropical
Medicine (LSHTM), Sangath in Goa, the Schizophrenia
Research Foundation (SCARF) in Chennai, the National
Institute of Mental Health and Neuroscience (NIM-
HANS) in Bangalore and Parivartan and Nirmittee in
Satara. In Goa and in Satara, the individual collaborators
are Psychiatrists working in the private sector.
Methods/Design
Study design
Effectiveness, parallel group, randomised controlled trial
design with unequal allocation of participants between arms.
The two arms of the study (allocation ration 2:1) will comp-
are people with schizophrenia allocated to receive: (i) FBC+
CCBC, or (ii) FBC only, with follow up over 12 months.
Setting
The trial will be conducted in three sites in India- in four
rural blocks or sub-districts in the southern Indian state
of Tamil Nadu and in two sites in western India, - across
the state of Goa and in Satara in the state of Maharash-
tra. The relevant details of the sites are summarized in
Table 1. These three sites have been chosen to reflect a
diversity of health system contexts, to strengthen the
generalisability of the study findings and to meet trial
recruitment targets within the allocated timeframe.
Description of the Interventions
The collaborative community based care (CCBC) intervention
The CCBC intervention is underpinned by three key
principles:
￿ firstly, the intervention is planned and implemen-
ted for each participant in close collaboration
between the person with schizophrenia, the primary
care giver(s) and the treatment team members (com-
prising the lay CHW, a supervising Psychiatric Social
Worker and the treating Psychiatrist);
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ible manner that reflects the unique needs of the
person with schizophrenia and their caregivers and;
￿ thirdly, that the intervention will promote respect,
autonomy and dignity for the person with schizo-
phrenia and caregivers.
The inclusion of the specific treatment components
within the treatment package have been guided by:
￿ evidence that the treatment is locally feasible,
acceptable and potentially of low cost;
￿ evidence for the effectiveness of the treatment in
low and middle income settings and;
￿ evidence that it can be delivered by lay health
workers
The CCBC intervention will be coordinated and deliv-
ered by lay CHWs who have completed at least 10 years
of schooling and have been systematically trained at
each site over 6 weeks. The training is based on the
intervention manual that follows a modular structure
covering various aspects of the illness, specific com-
ponents of the intervention and the operational
Table 1 The characteristics of the COPSI trial sites
Site Tamil Nadu Goa Satara
Collaborators Schizophrenia Research Foundation
http://www.scarf.org
Consulting Psychiatrists in private sector Consulting Psychiatrists in private sector
and ‘Parivartan’ and ‘Nirmittee’
Type of service
provider
Non Government Organization (NGO) Private sector individual practices Mixed model- combination of private
consulting Psychiatrists and NGO’s
working in tandem
Catchment area
description
Population coverage of approximately
500,000.
Population coverage of approximately 1
million.
Population coverage of approximately 2.0
million from nearby urban and rural areas
Participants will be from 235 villages in
Kanchepuram district of Tamil Nadu.
Referrals treated from all parts of Goa. Referrals are from the surrounding urban
and rural areas of western Maharashtra
People with schizophrenia mainly from
rural settings.
People with schizophrenia mainly from
urban and peri-urban settings.
People with schizophrenia from both
rural and urban settings
Majority belong to lower socioeconomic
section of the community.
Predominantly middle and upper socio-
economic status population who can
afford private care.
Wide range of social classes represented.
Usually available
treatments at
facilities
Services available:
Out- patient care once every 2 weeks at
each of the community clinic centres.
Services available:
All collaborators are solo practitioners
Services available:
Out-patient care 6 days a week in
designated clinics
1 Psychiatrist, 1 Psychiatric Social Worker
and 1 trained Assistant available at each
centre during the clinic.
Out-patient care 6 days a week in
designated urban clinics
In-patient care provided through liaison
with private hospitals
IP care: In multi specialty hospital with
registered private psychiatric unit for 20
psychiatric beds.
Intervention:
Main treatments are antipsychotic and
other psychotropic medications and
brief counselling for families and
persons with schizophrenia.
Intervention:
Main treatments used are anti-psychotic
and other psychotropic medications with
brief advice and counselling for families
and persons with schizophrenia.
Intervention:
Main treatments used are anti-psychotic
and other psychotropic medications with
brief advice and counselling for families
and persons with schizophrenia
Description of usual care process:
Consultation lasts for about 20 minutes
and usually includes family members.
Description of usual care process:
Consultations last about 30 minutes and
usually include family members.
Description of usual care process:
Consultations last about 30 minutes and
usually include family members.
Costs of medicines:
Free medications are given to all
persons with schizophrenia attending
the community clinics.
Costs of medicines:
Medicines are purchased from
pharmacies entirely through out of
pocket expenses
Costs of medicines
Medicines are purchased from
pharmacies entirely through out of
pocket expenses
Whether any
community care
is already
available
No community care available No community care available No community care available
Number of
inpatient beds
Nil- referrals to existing hospitals when
necessary for acute care
On an as needed basis in private
hospitals
20
Average number
of total OP
attenders/week
50-60 200 400-500
Average number
of patients/week
meeting
eligibility criteria
6-8 5-6 10-12
Chatterjee et al. Trials 2011, 12:12
http://www.trialsjournal.com/content/12/1/12
Page 3 of 14requirements of the trial related documentation and
supervision http://www.sangath.com/details.php?
nav_id=60. The CHWs will be closely supervised at each
site by Psychiatric Social Workers working as designated
Intervention Coordinators. They will coordinate the
overall delivery of the intervention and assure the qual-
ity and fidelity of the intervention at the site. The treat-
ing Psychiatrists will provide clinical leadership for the
community care teams and ongoing supervision to
maintain safety and quality standards. Overall, the con-
tinued supervision of the CHWs through joint onsite
visits, weekly group meetings and in scheduled meetings
with the Psychiatrist is an essential component of the
CCBC intervention.
The treatments included in the intervention package
are:
￿ structured psycho-educational information about
various issues related to the understanding and
proactive management of the illness for the partici-
pant and the care givers as well as specific efforts to
identify and address experiences of stigma and
discrimination
￿ adherence management strategies to reduce the
rates of non-adherence to treatments
￿ health promotion strategies to improve the physical
health status of people with schizophrenia
￿ Specific rehabilitation strategies to improve the
personal, social and vocational functioning of
participants
￿ Linkage to self help groups and other methods of
user led support
￿ Developing networks with community agencies to
address social problems in the family like poverty or
interpersonal disputes and facilitate a supportive fra-
mework for participants to seek employment and
access to social and legal benefits
The intervention is delivered in three phases. In the
initial, 3 month intensive engagement phase,t h ek e y
tasks will include developing a positive therapeutic alli-
ance with the person with schizophrenia and care givers,
conducting the needs assessment and generating the
collaborative individual treatment plan. There will also
be a focus on identifying and addressing familial social
difficulties that have an adverse impact on the person
with schizophrenia, adherence management and struc-
tured psycho-education sessions. We anticipate that
CHWs will conduct 6-8 home based (or other conveni-
ent location nominated by the person and care givers)
sessions during this phase.
In the second, stabilization phase during months 4-7,
the CHWs will conduct a total of 6-8 fortnightly ses-
sions. In this phase, the focus will be on addressing the
unmet or partially met needs from the first phase, rein-
force psycho-education and adherence, and introduce
other components like health promotion, rehabilitation
needs assessment and interventions (for example,
improving activities of daily living skills and social skills
training), and improving social interactions within and
outside of the family.
In the final, maintenance phase during months 8-12,
the CHWs will conduct 6 sessions. In this phase we
intend to reinforce the progress made, discuss strategies
to deal with distressing symptoms, discuss ways of deal-
ing with experiences of stigma and discrimination, focus
on restoration of social and economic roles, generate a
relapse prevention plan and address remaining unmet
needs, to the extent possible before a carefully planned
termination.
In total, we anticipate that each participant in the
CCBC arm will receive a maximum of 22 planned con-
tacts during the 12 months of the intervention, and that
each CHW will carry a maximum case load of 25 people
with schizophrenia at any one time. In evaluating the
intervention, we have set an a priori definition of ‘mini-
mum adequate’ as being 12 sessions of the CCBC ses-
sions delivered over 12 months.
All informational materials meant for the use of parti-
cipants and caregivers has been systematically translated
into the five regional languages used across the trial
sites. The intervention has been systematically piloted at
each of the sites. Based on the results of the field test-
ing, the final content and process of the phase specific
delivery of the intervention has been manualised, as
mentioned earlier.
Facility based Care (FBC)
‘Facility Based Care’ is the care usually provided by
mental health practitioners for persons with schizophre-
nia and their families. In two of the sites i.e. Goa and
Satara, Psychiatrists in the private sector are the primary
care providers with trained assistants recording essential
socio demographic details in some of these clinics. In
rural Tamil Nadu, a team of three persons are involved
in the clinics. A trained assistant records essential socio
demographic details of all persons who come to the
clinic. A brief clinical history is then elicited by the Psy-
chiatric Social worker (PSW) who then presents the
findings to the clinic Psychiatrist for detailed assessment
and treatment planning. In Goa and in Satara, the Psy-
chiatrists are the first point of contact and, for the most
part, conduct all necessary procedures themselves.
Across all settings, consultations last from 15-45 min-
utes; persons with schizophrenia presenting for the first
time are reviewed once or twice a month while those
who are clinically stable are reviewed more flexibly-
once a month- 3 months. Almost all persons with schi-
zophrenia in these facilities are prescribed psychotropic
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being preferred (as in India, these newer drugs are cost
comparable with the older antipsychotic drugs) while
the use of antidepressants, anticholinergic, sedatives and
modified Electroconvulsive treatment (ECT) is based on
individual clinical needs. All psychiatrists also provide
specific information about the illness, encourage adher-
ence and discuss other specific concerns that the person
with schizophrenia or their family members have; all of
these are provided on an ‘as needed’ basis. The salient
difference between the two arms is that in the CCBC
arm, a complex psychosocial intervention, tailored
towards individual needs, will be delivered in an accessi-
ble (home based) and structured manner by a dedicated
C H W .T h e r ew i l lb en og u i d e l i n e so rp r o t o c o l sm a d e
available to Psychiatrists for the medical treatment of
participants as this is more representative of usual care
in India. FBC will continue to be available to partici-
pants in both study arms and treating Psychiatrists will
be unblinded while providing care for participants.
Selection of participants
COPSI is an effectiveness trial and to improve the gen-
eralisability of the study results, we will:
￿ recruit persons with schizophrenia into the trial
from those who present to routine, ‘real life’ treat-
ment settings and
￿ include those persons with schizophrenia for
whom community based care is justified even in low
resource countries.
Thus, the inclusion criteria for participating in the
trial are:
￿ Trial participants must be between the ages of 16-
60 years
￿ Have a primary diagnosis of schizophrenia as per
ICD-10 DCR criteria [11]
￿ Have had an illness duration of at least 12 months
and an overall moderate severity of the illness based
on the Clinical Global Impression-Schizophrenia
(CGI-SCH) scale [12] rating. This reflects the thresh-
old at which additional community care is warranted
in resource constrained settings where community
based care can realistically be offered only for those
with high needs.
￿ Be residing within the study catchment area for the
next 12 months.
In the Tamil Nadu site, participants will be selected
from those identified through a community survey in
the study area and will then be referred to community
clinics for assessment by the Psychiatrists. In Goa and
Satara, participants will be approached for recruitment
from the clinical practices of the collaborating Psychia-
trists. In these settings, we anticipate two pathways for
recruitment: (a) people with schizophrenia from within
the existing caseloads at each of the sites who meet
inclusion criteria; and (b) people with schizophrenia
who have presented for care for the first time and meet
all inclusion criteria.
The flow of participants in the trial
The collaborating Psychiatrists will identify all persons
with a primary diagnosis of ICD 10-DCR schizophrenia
in their setting by using a checklist. All persons with
schizophrenia will be assigned a unique identification
number and the Psychiatrist will fill out an initial
screening form to confirm eligibility and record other
basic socio-demographic and clinical details. From this
‘universe’ of persons with schizophrenia, for those who
meet all inclusion criteria, the Psychiatrists will provide
a brief overview of the trial together with a standard
flier outlining the purpose of the trial (that is translated
to all relevant local languages) and ask the person and
the caregiver (s) whether they are interested in partici-
pating in the trial. If the person or the caregiver does
not agree to proceed further, the Psychiatrist will briefly
record their reasons for their not agreeing, whenever
possible. For those who have refused, the Psychiatrist
has the option of revisiting their participation during
the course of the recruitment period. If both are inter-
ested to continue, the Psychiatrist will then fill out addi-
tional clinical details and take written (for non literate
persons, their left thumb impression will be taken)
assent for the independent consent procedure.
Subsequently, an independent, trained researcher will
conduct the informed consent interview. The consent
procedure has been specially designed to provide ade-
quate information about the trial in a manner that is
matched to the literacy levels of the participant and
caregiver and to minimize the cognitive difficulties that
persons with schizophrenia commonly face in proces-
sing information for making an informed decision [13].
After the procedure, the participant and the caregivers
make an informed choice to participate or not. At this
stage, the researcher will record the reasons for partici-
pation or refusal, whenever possible. Once informed
consent has been obtained, trained researchers will com-
plete the baseline quantitative assessments for both the
participant and the caregiver(s) who are then assigned a
unique trial ID.
From this overall sample of participants, a purposively
selected sub sample of 12 participant and their care-
givers will be chosen at each of the three sites for the
additional baseline qualitative interviews. Once all base-
line assessments have been completed, participants will
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study for the next 12 months.
The identification, registration and subsequent flow of
participants in the trial will be governed by the trial
standard operational protocol (SOP) at all sites. This
will be monitored closely using a set of process indica-
tors and any deviations from the protocol and the rea-
sons for the same will be carefully recorded. The flow of
participants during the conduct of the trial, illustrated in
Figure 1, will be monitored and reported in compliance
with the recent CONSORT recommendations [14].
Randomisation
Generating the allocation list
Three lists have been generated independently by the
Trial Statistician in London, one for each site, and trans-
mitted to the site Data Managers prior to the com-
mencement of the recruitment for the trial. The pre
determined allocation sequence cannot be altered during
the recruitment of participants in the trial.
Allocation concealment
The site Data Managers will be entrusted with keeping
the allocation list secure (through password protected
files). The matching of the study numbers of the
recruited participants with their randomization numbers
and the concealment of randomization from inter-
viewers will also be managed by the central Data Man-
ager to ensure that no one has access to the allocation
list.
Implementation
For logistic reasons, the site Data Managers will be
responsible for assigning the unique trial ID for each
randomized participant in the trial; if the participant is
assigned to the CCBC arm, the Data Manager will notify
the site intervention coordinator and pass on the
required contact information. For participants in both
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Did not receive allocated intervention (give reasons) (n=)
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Discontinued intervention (give reasons) (n=) 
     
Analysed for 6 and 12 month outcomes:  (n=)
     
Excluded from analysis (give reasons) (n=0)
Analysed for 6 and 12 month outcomes: (n=) 
Excluded from analysis (give reasons) (n=0)
Figure 1 Flow of participants during the conduct of the trial
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Psychiatrists are provided with the specially designed
clinical booklet to record treatment details for the next
12 months.
For statistical reasons (see ‘sample size estimation’
below) there will be unequal allocation, with a larger
number in the intervention arm. The rationale for the
unequal randomization is the additional source of varia-
bility in the intervention arm - the effect of individual
community health workers which is built into the analy-
sis and allowed for in the sample size as recommended
in the recent CONSORT guidelines for non pharmaco-
logical trial design and reporting [15]. It is difficult to
precisely estimate the magnitude of this extra variability
(the intra-class correlation), but the value chosen for the
intervention arm of 0.1 is conservative: a recent review
of a large number of primary care variables found the
inter-quartile range to be 0 to 0.032 [16]. For practical
reasons, the ratio of numbers in the two arms was fixed
at a whole number; for the study this has been chosen
to be 2:1. The method of allocation will be through the
use of permuted blocks, with random block sizes chosen
from 3, 6 and 9 using the ‘ralloc’ routine in Stata.
Outcome assessments
1. Quantitative assessments
For the primary outcome assessments, we will record
the symptoms of schizophrenia at baseline and at 12
months, with the Positive and Negative Syndrome Scale
(PANSS) [17].
For measuring the change in disability, we will use the
Indian Disability Evaluation and Assessment Scale
(IDEAS) [18] at baseline, 6 and 12 months to generate
information on the time course of the effect of the
intervention.
For the secondary outcome assessment for persons
with schizophrenia, we will measure:
￿ Adherence with antipsychotic medication: For each
participant, we will assess adherence at baseline (if
on treatment) and at 6 and 12 months using a 5
point ordinal scale developed for the study.
￿ For measuring various dimensions of the experience
of stigma and discrimination, we will use the Discri-
mination and Stigma Scale (DISC) [19] at baseline
and at 12 months.
￿ An item on willingness to disclose mental illness
[20] will be used for participants at baseline and at
12 months to assess their readiness to disclose their
illness.
￿ The Alienation subscale of the Internalized Stigma
of Mental Illness (ISMI) scale [21] will be used to
measure the subjective experience of internalized
stigma of participants at baseline and at 12 months.
￿ Finally, to estimate the Quality Adjusted Life Years
(QALY), we will use the widely used Euroqol (EQ-
5D) [22] at baseline and at 12 months.
The secondary outcome measure for the primary
care givers are:
￿ The family burden of caring will be measured at
b a s e l i n ea n da t1 2m o n t h sb yu s i n gt h eB u r d e n
Assessment Schedule (BAS) which has been devel-
oped and used widely in India [23].
￿ The knowledge and attitudes of family members
about schizophrenia will be assessed at baseline and
at 12 months by using the Knowledge about Schizo-
phrenia Interview (KASI) [24]
￿ A section of the ‘Family Interview Schedule’ (FIS)
developed for the International Study of Schizophre-
nia (ISOS) [25] and previously used in a study in
India [26] will be employed to assess the experiences
of stigma and discrimination experienced by the pri-
mary caregivers.
￿ The item on willingness to disclose mental illness
[20] will be used for caregivers after suitable
modification.
￿ The caregiver summary assessment of the partici-
pant’s degree of adherence will be rated by using the
same 5 point ordinal scale used for participants. To
improve the validity of adherence ratings, we will
complete a systematic assessment of medication use
for the last 2 months (to minimize recall bias over
the 6 month period); this 2 month adherence will be
extrapolated for the last 6 months.
For the economic aspects of the study, we will ask
caregivers to complete the Cost of Illness Schedule
(CIS) that has been developed and used in India in com-
munity studies before [27] at baseline, 6 and 12 months.
In addition, we will record the type, dosage and duration
of medications prescribed by treating Psychiatrists dur-
ing each of the contacts with participants as well as the
number of inpatient days for each participant - this data
will be available from the Psychiatrists’ structured
records. Service costs will be calculated by attaching
locally calculated unit costs to these data. In addition,
we will use the Euroqol EQ-5D with participants for
assessing Quality of Life Years at baseline and at 12
months.
The adherence measures and the CIS will be repeated
at 6 months, as will the IDEAS. For the CIS and adher-
ence measures, the rationale is to minimize recall bias.
The IDEAS will be used at 6 months to have an interim
measure for one of the primary outcomes that is brief
and easy to complete.
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study.
Finally, we will record other presence of co-morbid
mental and physical disorders and relevant socio- demo-
graphic information about the participant, the primary
caregiver and the family during the baseline assessment.
Outcome evaluation/masking
The outcome evaluation of symptoms using the PANSS
will be carried out by mental health professionals who
will be trained, certified and supervised by experts. All
other outcome measurements will be conducted by
trained graduate researchers. The selected researchers
will be trained in a structured manner across the sites
to ensure adequate inter-rater reliability for all scale
items across the sites. To maintain blinding of these
assessments, all outcome measures will be administered
by researchers who are independent of the intervention
and blind to the allocation of treatment. Since neither
the participant nor the family caregivers will be blind to
their allocation status at the time of the 6 and 12 month
interviews, we intend to minimize the chances of
unmasking during the outcome assessments by institut-
ing the following measures:
￿ The intervention and research teams at the sites
will not have any interactions during the trial with
separate physical location and administrative
management.
￿ The researchers are told that they are evaluating
two interventions and that there is genuine equipoise
about which one is better
￿ Orient the families prior to each assessment that
they should not disclose whether or not they are
receiving home visits from the CHW and
￿ Complete the primary outcome measures (PANSS
and the IDEAS) first.
2. Qualitative Data Collection
The purpose of qualitative data collection within the
trial is to describe the experiences of participants and
caregivers in the two arms relating to the care received
(including acceptability and perceived effect), the impact
of the illness and experiences of stigma and discrimina-
tion. We also intend to describe changes in these
domains over the follow-up period, explore attributions
of changes and to compare outcomes between the two
arms of the trial.
We intend to recruit approximately 36 participants
and 36 primary caregivers (= 36 participant - caregiver
dyads) at each site for the in-depth-interviews at base-
line; however, numbers may be increased if indicated by
ongoing analyses. Separate consent will be obtained
from participants and caregiver(s) for these qualitative
interviews. The same participants and caregivers who
are interviewed at baseline will be approached for
follow-up interviews 12 months later after the final
quantitative outcome assessments are completed.
The sampling strategy is purposive, taking into
account participant’s gender and the degree to which
stigma is a concern to the participant as assessed by
quantitative measures. Efforts will be made to purpo-
sively interview outliers. Sampling will further aim to
ensure sample variability at each research site with
regards to severity of illness, highest education levels in
the household, type of relationship of caregiver to
patient and other themes that may emerge as important
from ongoing analyses.
In addition, we propose to conduct in-depth-inter-
views with Psychiatrists and CHWs at endpoint to
ascertain their satisfaction with work, the adequacy of
training and supervision and their impressions on the
impact of the program.
Quality assurance and fidelity management
To ensure that the CCBC intervention is of adequate
fidelity, we will collate the intervention process indica-
tors related to the delivery of the intervention (Table 2)
every month from each site. This will be monitored to
check for significant divergence from per protocol
norms between the sites; any such divergence will lead
to suitable corrective action to harmonize the interven-
tion across the sites.
For quality assurance purposes, key CCBC sessions at
each site (needs assessment, 3 and 6 month reviews and
termination session) will be rated by intervention coor-
dinators during joint home visits with the CHWs. Feed-
back for improving the methods and delivery of the
intervention will be provided to all CHWs to achieve
and maintain pre determined quality benchmarks during
the trial.
Systematic efforts will be made to ensure that both
quantitative outcome measurements as well as qualita-
tive interviews will be of adequate quality across the
sites. The researchers will be supervised in a weekly
group meeting with the study coordinators at each site.
In addition, 5% of all interviews at each site will be
assessed through joint onsite visits with the coordinator
who will provide feedback using a specially designed
assessment form to confirm that the overall pre-set
quality benchmarks are achieved and maintained during
the trial. For the qualitative data, there will be regular
supervision available for researchers at each site with
regular group and individual supervision related to
interview methods, data translation and transcription.
To ensure the safety of the researchers while conduct-
ing interviews at the homes of participants, all initial vis-
its will be made by a team of 2 researchers who will
have notified the Coordinators about their location.
Researchers have also been trained to recognize possible
dangers and threats and respond to them appropriately
Chatterjee et al. Trials 2011, 12:12
http://www.trialsjournal.com/content/12/1/12
Page 8 of 14Table 2 Summary table of data collection in COPSI
TYPE OF DATA
1. Quantitative: (using a
combination of programmed
palmtops and paper and pencil
methods)
Measured at:
Primary Outcome Interviewee Outcome assessment scale description 0
month
6
months
12
months
Symptoms Person with schizophrenia Positive and Negative Syndrome Scale (PANSS). The
PANSS has 30 items to record current
psychopathology on 3 domains- positive
symptoms, negative symptoms and general
psychopathology; each item rated on 1-7 scale thus
having a total score range of 30-210.
XX
Disability Primary caregivers Indian Disability Evaluation and Assessment Scale
(IDEAS). For the IDEAS evaluation, the participant is
assessed on 4 domains- Self Care, Interpersonal
Activities, Communication and Understanding and
Work. The scale generates a global score of 0-20
with increasing scores indicating more severe
disabilities
XX X
Secondary outcomes
Stigma and discrimination Person with schizophrenia Discrimination and Stigma Scale (DISC). The version
to be used is based on DISC-12, but was adapted
for the study. The revised version has 30 items in
total, all rated on a 4 point Likert scale ranging
from ‘not at all’ to ‘a lot’.
XX
There are 20 items in the Negative Discrimination
Subscale plus 1 new negative discrimination item
generated for the trial, 4 items on anticipated
discrimination, 1 item relating to efforts of
overcoming stigma and discrimination and 4 items
for recording experiences of positive discrimination.
Internalized stigma The Internalized Stigma of Mental Illness (ISMI) scale
is designed to measure the subjective experience
of internalized stigma and consists of 5 subscales.
For the study, the ‘Alienation’ subscale was chosen.
It consists of 6 items which are scored on a 4-point
Likert scale ranging from ‘strongly disagree’ to
‘strongly agree’.
XX
Willingness to disclose illness An item on willingness to disclose mental illness
rated on a 5-point Likert scale ranging from ‘very
uncomfortable’ to ‘very comfortable’.
XX
Quality of life Euroqol EQ-5D that has a descriptive assessment of
5 domains: mobility, self-care, usual activities, pain/
discomfort, anxiety/depression. Each domain is
coded as level 1, 2 or 3 and combined into a 5
digit code together with a summary visual
analogue scale assessment of quality of life score 0-
100.
XX
Subjective rating of adherence
with antipsychotic medication
Adherence rating tool with 5 ordinal ratings to
describe a range of adherence (from non adherent-
fully adherent)
XX X
Knowledge of and attitudes
towards illness
Primary caregiver(s) Knowledge about Schizophrenia Interview (KASI).
There are 6 domains of understanding that are
assessed; the maximum score for each domain
being 4.
XX
The family burden of caring The Burden Assessment Schedule (BAS). The BAS is
scored on 40 items with a maximum score of 120;
the minimum score can be less than 40 as some
questions can be rated as ‘not applicable’.
XX
Costs of illness Cost of Illness Schedule (CIS) XX X
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techniques). All researchers will also have access to
mobile phones to discuss any potentially difficult situa-
tion with their supervisor. In case of any untoward inci-
dent, researchers will have provision for debriefing and
a review of the safety arrangements.
Statistical issues
Sample size estimation
Based on the data from the earlier non randomized
study [9], it was assumed that a difference of at least
20% reduction on the PANSS total score of 65 (sd 10) i.
e. 13 points to 52, would be highly clinically significant.
The estimated pre-post correlation was 0.4 (reducing
the effective sd to 9 after adjusting for baseline). The
intra-class correlation within the three sites in the con-
trol arm was set at 0.05; in the intervention arm (which
would include within-CHW as well as within-site
effects) it was set at a higher level of 0.1; alpha was set
as 0.05. Using the method of Roberts and Roberts [28]
with the Stata routine cluspower will give us 98% power
to detect this difference. This is equivalent to a large
standardised effect size, 1.44. For effect sizes of 1 (9
PANSS units) and 0.8 (7.2 PANSS units) the power
would be approximately 90% and 80% respectively.
Table 2 Summary table of data collection in COPSI (Continued)
Adherence with antipsychotic
medication
Adherence rating tool with 5 ordinal ratings
ranging from non- adherent to fully adherent
supplemented by audit of actual medicine use over
last 2 months that is extrapolated to the previous 6
month period
XX X
Experiences of stigma and
discrimination
14 items from the Stigma section of the Family
Interview Schedule (FIS) will be used to assess the
experiences of stigma the primary caregivers. These
cover several aspects of internalized stigma as well
including perceived need to conceal the illness and
anticipated discrimination. The items are scored on
a 4-point Likert scale (0 - 3) ranging from ‘not at all’
to ‘a lot’.
XX
Willingness to disclose Item on willingness to disclose mental illness rated
on a 5-point Likert scale ranging from ‘very
uncomfortable’ to ‘very comfortable’.
XX
2. Clinical outcomes of interest: Information source How recorded? Frequency of
measurement
Treating Psychiatrist’s assessment
of overall clinical change
Clinical records maintained
by treating Psychiatrist
Clinical Global Impression-Schizophrenia ‘overall
change’ scale section
Every 3 months
Treating Psychiatrist’s assessment
of adherence
5 point nominal measure, similar to that used by
participants and caregivers
Every 3 months
Inpatient stay details Recorded for each such episode by treating
Psychiatrist
Collated at endpoint
Relapse of illness Relapse is defined as clinically significant
exacerbations of symptoms after at least 2 months
of well- being; clinical significance involves meeting
at least 2 of the following 3 criteria: marked
increase in positive symptoms, hospitalization for
acute care and significant increase in dosage of
antipsychotic medications
Collated at endpoint
Serious antipsychotic medication
side effects
As above; also during by 6
and 12 month outcome
assessments.
Collated at endpoint
3. Process indicators
A. For participants in both arms of
study
Clinical records maintained
by treating Psychiatrist
Number of contacts with treating Psychiatrists Type
(face to face or telephone) contacts Treatment
details- use of psychotropic medications and
Electro Convulsive Treatments
B. For participants in the CCBC arm Individual care plan records
maintained by the
Community Health Workers’
(CHW’s)
The delivery of the components of the intervention
as per protocol over the 3 phases of the
intervention
Collated at endpoint
Per protocol supervision for CHW’s Every 3 months
Total number of contact by the CHW’s during the
12 month period of the intervention
Every 3 months
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282 to allow for 15% attrition and rounded up to allow
for a 2:1 randomisation within each site. The total
number of participants was then divided slightly
unequally between sites for reasons of feasibility. A
total of 188 persons with schizophrenia will be allo-
cated to the CCBC arm while 94 persons will be allo-
cated to the FBC arm.
Data management and analysis Findings will be
reported according to the revised CONSORT guidelines
[14]. No interim analyses are planned apart from base-
line comparisons. The statistical package Stata will be
used for the quantitative analysis. In accordance with
good trial practices, data will be retained for 7 years
after completion of the trial.
Descriptive summaries of socio-demographic and clin-
ical data will be provided for all trial participants at
baseline, and for outcome measures at baseline, 6-
month and 12-month follow up points; this will include
means and standard deviations, or proportions, in the
two arms, as appropriate. Scale and subscale totals with
missing items will be pro-rated (i.e. based on the mean
of those items that are present) if 20% or fewer items
are missing. The PANSS and the IDEAS will be sum-
marised in terms of the total score, the separate sub
scores of the different domains and the proportion of
patients improving by >20% from baseline. Histograms
within each arm will be used to assess normality of the
distribution of the data, to identify any outliers and
check for data errors. The proportion of participants
who are fully, partially or non- adherent to antipsychotic
treatment (derived from the adherence ratings of pri-
mary caregivers) will be reported for both arms. CHW
characteristics such as completed years of education and
caseload will also be described.
The data will be analysed under intention-to-treat
assumptions (i.e. all those with at least one follow up
measurement will be analysed in arms as randomised).
The 12-month PANSS total score, adjusted for PANSS
scores at baseline and site (using analysis of covariance),
and including clustering effects of CHWs, will be used
for determining the comparative effects of the two arms
on this primary outcome of the study. The disability
score generated by the IDEAS will be similarly analysed;
in addition, a longitudinal analysis including both 6- and
12-month outcomes will also be performed using a GEE
or random effects model including a time x treatment
term allowing for modelling changes over time. Residual
analysis will be performed to check the distribution of
the data and to detect outliers. Logistic regression analy-
sis with >20% reduction in PANSS at 12 months as the
dependent variable will be performed. Secondary out-
comes at 12 months will be treated in a similar way to
the primary outcome; of the secondary outcomes,
adherence will be measured at the 6-month point as
well as the 12-month point.
A number of sensitivity analyses for the primary out-
come are planned to be carried out. Regression models
will be re-estimated including possible confounders such
as participant characteristics that differ at baseline and
may be associated with outcome (e.g. age, gender, dura-
tion of illness, socioeconomic status and education) and
CHW characteristics like education and caseload; impu-
tation of missing baseline covariates will be performed if
there are more than 10% missing and analyses will be
repeated.
Subgroup analyses will include site and gender as
interactions with treatment arm to estimate differential
effects, and further analyses will investigate the effect of
engagement with the interventions on outcome. In addi-
tion to the primary intention-to-treat analysis, the effect
of participants in the CCBC arm receiving the minimum
effective number of sessions as defined in the protocol
will also be estimated. Power for these subgroup ana-
lyses has not been specifically allowed for, and so they
will be treated as exploratory.
Analysis plan for economic data Service costs will be
calculated by combining the service use data with
appropriate local unit costs. Cost comparisons will be
made using bootstrapping methods to account for
skewed data. Cost-effectiveness will be assessed by com-
bining costs with outcomes in the form of incremental
cost-effectiveness ratios which will show the extra cost
incurred (if any) to produce a unit improvement in the
main outcomes (symptoms and disability) as well as
QALYs (measured using the EQ-5D combined with
appropriate utility weights). Uncertainty around cost-
effectiveness estimates will be explored using cost-effec-
tiveness planes and interpretation will be aided using
cost-effectiveness acceptability curves.
Analyses plan of qualitative data Analyses of inter-
view data will commence as data collection is ongoing
and will involve importing interview transcripts into
qualitative analysis software (NVivo8) for coding and
identification of key themes. Analyses of the baseline
qualitative data will explore illness experiences of people
with schizophrenia and their caregivers, with a particular
focus on experiences of stigma and discrimination.
As part of the 12-month follow-up qualitative ana-
lyses, treatment arms will be compared with regards to
themes such as the impact of the illness on persons
with schizophrenia and caregivers including experiences
of stigma and discrimination, met and unmet needs and
other themes that emerge as important from the data.
There will also be a focus on understanding the experi-
ences of care received, including their acceptability and
perceived effect, perceptionso fi n t e r a c t i o n sw i t hs t a f f
and attributions of changes from entry into the trial to
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negative consequences of CCBC will be sought out. Staff
interviews will concentrate on staff’s perspectives on the
impact of the intervention on the study outcomes.
Trial management and monitoring The COPSI study
will be conducted according to the good clinical practice
guidelines recommended for conducting multi site ran-
domized controlled trials. There will be a dedicated
Trial Coordinator who will coordinate the recruitment
and progress of the trial in conjunction with each of the
site Project Management Committees set up for this
purpose.
Ethical considerations Even though there is observa-
tional evidence from uncontrolled studies about the
effectiveness of community based interventions, there is
genuine clinical equipoise regarding the question of the
effectiveness and affordability of community care in Low
and Middle Income Countries (LAMIC). This trial is
justified in this context of paucity of evidence from such
contexts, derived from rigorous controlled studies, about
the clinical and cost effectiveness of community services
for people with schizophrenia.
Underpowered trials are unethical and we have made
provisions to have adequate power in the COPSI study.
We have calculated the sample size in a systematic fash-
ion at several levels. This includes having a threshold of
95% power (using alpha = 0.05) for detecting a clinically
significant difference in the primary outcome measure
between the two arms. We have also specifically
addressed the issue of clustering effects within treatment
sites and CHWs delivering the intervention in calculat-
ing our sample size. Based on these assumptions, we
feel the study is adequately powered to detect differ-
ences in a robust manner to generate valid results.
We will ensure that the rights of participants are pro-
tected during the conduct of the trial in accordance
with good practice ethical obligations. To address the
problems associated with obtaining consent from people
with schizophrenia who are symptomatic and sometimes
non-literate, the consent procedure will be carried out
using non technical language and, in a manner designed
to enhance the intake and retention of information. This
includes the use of a specially designed flipchart illus-
trating the key components of the information relevant
to informed decision making. Irrespective of the deci-
sion to participate or not, no person with schizophrenia
will be deprived of any treatment s/he will ordinarily
receive. Participants will be free to withdraw from the
study at any stage without compromising their usual
clinical care. Finally, informed consent to participate in
the trial will be recorded by using a form that is in com-
pliance with the Helsinki Declaration and Good Clinical
Practice (GCP) guidelines [29]; these have been
approved by regulatory bodies.
Arrangements will be made to comply with suggested
GCP guidelines in related to protecting the confidential-
ity of personal data principally through procedures to
separate study data and participant identifiable data. For
the quantitative data, the data gathered in the palmtops
for each participant and the family at baseline will be
checked by the Data Manager who will remove all per-
sonal identification items (to be kept as a separate file
with restricted password protected access to the Data
Manager only) and assign a unique Trial ID. All future
data will be collected and collated using only the ID
number. Regarding the qualitative data set, participant
and caregiver files will be kept in locked cabinets with
only the interviewers and the research coordinator hav-
ing access. All identifying information (i.e. name, socio-
demographic data etc) will be removed from the inter-
view data and kept separately. Both the individuals and
caregivers will be given unique ID codes (i.e. not having
name/any other identifying information). Soft copies of
transcriptions will be kept in password protected files in
a secure computer. Transcriptions will have no identify-
ing information.
Formal ethical approval for conducting the trial has
been sought and obtained from the ethics committees at
the Kings’ College, London (PNM/08/09-121), the Lon-
don School of Hygiene and Tropical Medicine (approval
number 5579) and from the respective Institutional
Review Boards at SCARF and Sangath. The trial is regis-
tered with the International Society for the Registration
of Clinical Trials and the allocated unique ID number is
ISRCTN 56877013.
The trial will be regulated by an independent Trial
Monitoring Committee (TMC) represented by experts
and user representatives who have reviewed and for-
mally approved the protocol before commencing
recruitment. The TMC will be provided with quarterly
updates describing the trial progress during the recruit-
ment period and every 6 months thereafter. A critical
incident register will be maintained during the study to
record four specific serious adverse events- death, sui-
cide attempt, hospitalization (from any cause) and ser-
ious medication side effects like neuroleptic malignant
syndrome, tardive dyskinesia, akathisia and tremors for
participants in both arms of the study; these are in
accordance with the recommendations of the TMC.
Across both arms, these adverse events will be recorded
by the treating Psychiatrists as they occur and by the
researchers who will be collecting quantitative data at 6
and 12 months. For participants in the CCBC arm, the
concerned CHW will also report these events. The
reporting and per protocol action taken for each
adverse event will be made available the TMC during
the updates. The TMC is also empowered to indepen-
dently review the ethical and data management
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norms.
The TMC can examine the unblinded outcome and
adverse event data during the planned annual review
meetings and will be consulted before the public report-
ing of the results of the study. Updates will be provided
to all concerned ethics committees of major changes in
the protocol, if necessary.
Discussion
Providing community based services for greater num-
bers of people with schizophrenia in low and middle
income countries is an urgent public health priority.
The COPSI randomized controlled trial builds on pre-
vious observational evidence of the feasibility, accept-
ability and effectiveness of CBR programs that
incorporated lay community health workers as the front
line service providers. This trial is designed to provide
q u a l i t ye v i d e n c ea b o u tt h ec linical effectiveness of the
intervention and the economic implications of the com-
munity intervention.
Given the ‘real life’ sample of subjects and the diver-
sity of the sites where the study will be conducted, we
believe that the results of the study will be generalisable
beyond the study population. If the results confirm the
hypotheses and CCBC intervention has additional clini-
cal benefits and is cost effective, this can have significant
impact on health policy related to the scaling up com-
munity care for people with schizophrenia in India and
other LAMIC. The results of the trial will be used
to inform policy makers and practitioners about the
benefits, necessary human resources and costs of a com-
munity based intervention that can be fronted by non-
specialist workers (working in tandem with specialists),
involve the person with schizophrenia and the family
and engage proactively with the local community in pro-
moting recovery and social inclusion.
Finally, through the detailed exploration of experi-
ences of stigma and discrimination and evaluation of the
intervention on stigma outcomes, the study will also
contribute to the limited evidence on felt experiences
and effective interventions to reduce stigma and discri-
mination for people with severe mental disorders in
LAMIC.
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